Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) traded down 3% on Wednesday . The stock traded as low as $12.00 and last traded at $12.01. 89,287 shares were traded during mid-day trading, a decline of 76% from the average session volume of 379,709 shares. The stock had previously closed at $12.37.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on KALV shares. TD Cowen began coverage on KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating and a $30.00 price objective for the company. JMP Securities began coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an "outperform" rating and a $19.00 price target on the stock. Bank of America started coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They set a "buy" rating and a $22.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Finally, Citizens Jmp raised KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $23.80.
View Our Latest Analysis on KALV
KalVista Pharmaceuticals Trading Down 0.9 %
The business's 50 day moving average price is $10.13 and its two-hundred day moving average price is $10.25. The stock has a market cap of $591.12 million, a P/E ratio of -3.27 and a beta of 0.76.
Insider Buying and Selling at KalVista Pharmaceuticals
In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par bought 100,000 shares of the company's stock in a transaction dated Wednesday, February 12th. The shares were purchased at an average price of $9.23 per share, for a total transaction of $923,000.00. Following the acquisition, the insider now owns 5,217,285 shares in the company, valued at approximately $48,155,540.55. This represents a 1.95 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 5,104 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $50,121.28. Following the completion of the transaction, the chief executive officer now owns 278,855 shares of the company's stock, valued at approximately $2,738,356.10. The trade was a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have bought 236,055 shares of company stock valued at $2,162,146 and have sold 17,292 shares valued at $184,625. Insiders own 10.50% of the company's stock.
Institutional Trading of KalVista Pharmaceuticals
A number of hedge funds have recently made changes to their positions in KALV. Suvretta Capital Management LLC raised its stake in KalVista Pharmaceuticals by 16.6% during the fourth quarter. Suvretta Capital Management LLC now owns 4,913,012 shares of the specialty pharmaceutical company's stock valued at $41,613,000 after buying an additional 701,007 shares during the last quarter. Tang Capital Management LLC increased its holdings in shares of KalVista Pharmaceuticals by 13.2% during the fourth quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company's stock valued at $41,451,000 after acquiring an additional 572,300 shares in the last quarter. Frazier Life Sciences Management L.P. increased its holdings in shares of KalVista Pharmaceuticals by 32.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company's stock valued at $41,400,000 after acquiring an additional 1,200,000 shares in the last quarter. Vestal Point Capital LP raised its position in shares of KalVista Pharmaceuticals by 19.3% in the 4th quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company's stock worth $40,402,000 after purchasing an additional 770,000 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in KalVista Pharmaceuticals by 4.9% in the 4th quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company's stock worth $19,102,000 after purchasing an additional 104,716 shares in the last quarter.
About KalVista Pharmaceuticals
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Featured Articles
Before you consider KalVista Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.
While KalVista Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
